Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study
Autor: | Yuho Najima, Takayoshi Tachibana, Yusuke Takeda, Yuya Koda, Yasuhisa Aoyama, Takashi Toya, Aiko Igarashi, Masatsugu Tanaka, Emiko Sakaida, Ryohei Abe, Makoto Onizuka, Takeshi Kobayashi, Noriko Doki, Kazuteru Ohashi, Heiwa Kanamori, Takuma Ishizaki, Akira Yokota, Satoshi Morita, Shinichiro Okamoto, Yoshinobu Kanda |
---|---|
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Annals of Hematology. 101:2719-2729 |
ISSN: | 1432-0584 0939-5555 2015-2019 |
Popis: | This 3+3 dose-escalation phase I multicenter study investigated the optimal dose of azacitidine (AZA) for post-hematopoietic stem cell transplantation (HSCT) maintenance, which remains unknown in Japan. Recipients of a first HSCT for high-risk myelodysplastic syndromes (MDS, n = 12) or acute myeloid leukemia (AML) with antecedent MDS (n = 3) received post-HSCT AZA maintenance in 2015-2019. The optimal AZA dose was defined as the dose at which 50-70% of patients can complete four cycles without dose-limiting toxicity (DLT). The initial dose level 1 was set as 30 mg/m |
Databáze: | OpenAIRE |
Externí odkaz: |